Stručni rad
https://doi.org/10.20471/LO.2019.47.02-03.13
Analysis of intermediate and poor prognostic group of patients with metastatic kidney cancer treated at the University Hospital Center Zagreb
Marko Bebek
orcid.org/0000-0001-7442-2626
; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia;
Maja Baučić
; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia;
Sanja Šandrk
; Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia;
Milena Gnjidić
orcid.org/0000-0003-2858-1428
; Division for Medical Oncology, Unit for Uro-Oncology, Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Marija Gamulin
; Division for Medical Oncology, Unit for Uro-Oncology, Department of Oncology, University Hospital Center Zagreb, Zagreb, Croatia
Sažetak
Forty two to 57% of patients with metastatic renal cell carcinoma (mRCC) receive the second-line therapy according to available data. In our analysis we wanted to determine the percentage of patients within intermediate/poor prognostic group mRCC who continued the treatment with the second line following progression on the first line and the percentage of patients who were not able to receive the second line treatment. Patients received sunitinib (first started on 12 August 2018) or pazopanib (first started on May 2014) at University Hospital Center Zagreb. The latest treatment started in December 2018. Our results show that 39.4% of patients who received sunitinib and 37.9% of patients who received pazopanib, did not receive the second line treatment, which is consistent with available data. The question arises whether we could have helped those patients if we had access to newer therapeutic options.
Ključne riječi
metastatic kidney cancer; treatment; sunitinib; pazopanib
Hrčak ID:
233624
URI
Datum izdavanja:
28.1.2020.
Posjeta: 1.193 *